KI-TOX-A3
Based on 1 Customer Validation
KI-TOX-A3 is a TOX protein-protein interaction inhibitor that blocks the TOX-KAT7 protein-protein interaction with an IC50 of 0.51 μM. KI-TOX-A3 induces proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses exhaustion of CD8+ T cells, and inhibits the proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 shows promise for use in studies of hematological malignancies such as T-ALL.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.15%
- CAS No.: 1351116-34-1
- Formule: C18H13N3O3
- Masse moléculaire:319.31
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
Description
In Vitro
KI-TOX-A3 (0.156-10 μM) potently inhibits the TOX-KAT7 protein-protein interaction in cell-free ELISA assays, with an IC50 of 0.51 μM[1].
KI-TOX-A3 (100 μM) binds directly to purified full-length TOX protein in cell-free ITC assays, with a Kd value of 1.05 μM[1].
KI-TOX-A3 (0.15-10 μM) binds directly to biotinylated full-length recombinant human TOX protein in cell-free SPR assays, with a Kd of 0.92 μM[1].
KI-TOX-A3 (20-40 μM) selectively competes for binding to TOX protein in Molt-4 cell lysates[1].
KI-TOX-A3 (0-10 μM) dose-dependently restores TOX protein-inhibited KAT7-mediated H3K14 acetylation in cell-free in vitro assays[1].
KI-TOX-A3 (5-10 μM; 24 h) inhibits the protein-protein interaction between TOX and KAT7 in Molt-4 T-ALL cells[1].
KI-TOX-A3 (96 h) exerts selective cytotoxicity against TOX-dependent T-ALL and CTCL cell lines, with IC50 values ranging from 2.0 μM to 6.3 μM after 96 h of treatment, whereas it shows much lower toxicity against TOX-independent cell lines[1].
KI-TOX-A3 (10 μM) induces S-phase cell cycle arrest in Jurkat T-ALL cells[1].
KI-TOX-A3 (5-10 μM; 4-12 h) induces proteasome-dependent degradation of TOX protein in Molt-4 T-ALL cells[1].
KI-TOX-A3 (0.625-10 μM; 2-12 h) dose-dependently reduces TOX mRNA levels in Jurkat T-ALL cells[1].
KI-TOX-A3 (2.5-10 μM; 24 h) reduces the expression of exhaustion markers TIM-3 and LAG-3, promotes the expression of effector cytokines, upregulates PD-1 expression in exhausted primary human CD8+ T cells, restores the cytotoxic activity of exhausted primary human CD8+ T cells against CD19+ Ramos cells, and restores the acetylation level of H3K14 in exhausted primary human CD8+ T cells to a level comparable to that of non-exhausted T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Molt-4 T-ALL cells
-
Concentration:5 μM, 10 μM
-
Incubation Time:0, 2, 4, 6, 8, 12 h (10 μM); 12 h (5 μM, 10 μM)
-
Result:Reduced TOX protein levels after 4 h of treatment at 10 μM; the proteasome inhibitor MG132 (HY-13259) (1 μM) rescued TOX protein levels in cells treated with 5 μM or 10 μM KI-TOX-A3 for 12 h, indicating proteasome-dependent degradation.
-
Cell Line:Jurkat T-ALL cells
-
Concentration:0.625, 1.25, 2.5, 5, 10 μM
-
Incubation Time:2, 4, 6, 8, 12 h
-
Result:Decreased TOX mRNA levels in a dose-dependent manner after 12 h of treatment; significant reductions in mRNA levels were observed after 4 h of 10 μM treatment, with further decreases over time.
-
Cell Line:Exhausted primary human CD8+ T cells, CD19+ Ramos cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Restored cytotoxic activity of exhausted CD8+ T cells against CD19+ Ramos cells, with ~50% improved killing efficiency compared to DMSO-treated exhausted T cells.
Chemical Information
-
CAS No. 1351116-34-1
-
Appearance Solid
-
Masse moléculaire 319.31
-
Formule C18H13N3O3
-
Color Yellow to orange
-
SMILES
OCC1=CC=C(C2=C(CC3=C4C=CC(O)=C3)C4=NC(N)=C2C#N)O1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 4.17 mg/mL (13.06 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Pull-down
The pull-down assay is an in vitro technique used to detect physical interactions between two or more proteins and an invaluable tool for confirming a predicted protein-protein interaction or identifying novel interacting partners. This method typically involves the use of affinity purification with various wash and elution steps.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay
Bimolecular fluorescence complementation detects protein-protein proximity in living or fixed cells by fusing two candidate interaction partners to nonfluorescent N- and C-terminal fragments of a fluorescent protein; when the partners interact or remain close enough, the fluorescent fragments complement, mature, and generate a fluorescent signal at the site of the protein complex. The BiFC readout is fluorescence intensity and subcellular localization of the reconstituted fluorophore, which reflects formation or stabilization of a protein complex rather than direct biochemical binding kinetics; BiFC is therefore useful for mapping where interactions occur in cancer cells, neurons, macrophages, organoid-derived cells, or drug-screening systems, but results should be validated by independent assays such as co-IP or Western blot. BiFC signal formation is delayed by fluorophore maturation and can stabilize otherwise transient complexes, so it is not a real-time reversible interaction assay
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
Protocol for Yeast Two-Hybrid (Y2H) Assay
The yeast two-hybrid assay detects binary protein-protein interactions by separating a transcription factor into a DNA-binding domain fused to a "bait" protein and a transcriptional activation domain fused to a "prey" protein; if bait and prey interact in yeast, the transcription factor is reconstituted and activates reporter genes such as HIS3, ADE2, lacZ, MEL1, or other selectable/readable reporters. The readout is yeast growth on selective medium and/or reporter activity, which reflects proximity-dependent transcriptional activation in the yeast nucleus rather than direct biochemical binding in the original mammalian, tumor, neuronal, macrophage, or organoid context. Because yeast two-hybrid can generate false positives and false negatives, interaction claims should be validated using independent assays such as co-immunoprecipitation, Western blot, immunofluorescence colocalization, BiFC, pull-down, or mammalian two-hybrid assays.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1318 mL | 15.6588 mL | 31.3175 mL | 78.2938 mL |
| 5 mM | 0.6264 mL | 3.1318 mL | 6.2635 mL | 15.6588 mL | |
| 10 mM | 0.3132 mL | 1.5659 mL | 3.1318 mL | 7.8294 mL |